These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ailanthone reverses multidrug resistance by inhibiting the P-glycoprotein-mediated efflux in resistant K562/A02 cells. Han F; Liu G; Sun C; Wei J Cell Mol Biol (Noisy-le-grand); 2018 Dec; 64(15):55-61. PubMed ID: 30672437 [TBL] [Abstract][Full Text] [Related]
4. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633 [TBL] [Abstract][Full Text] [Related]
5. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Zhang ZL; Jiang QC; Wang SR Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822 [TBL] [Abstract][Full Text] [Related]
6. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065 [TBL] [Abstract][Full Text] [Related]
7. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528 [TBL] [Abstract][Full Text] [Related]
8. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells. Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047 [TBL] [Abstract][Full Text] [Related]
9. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. Pan J; Miao D; Chen L Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439 [TBL] [Abstract][Full Text] [Related]
11. Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. Qiu Q; Shi W; Li Z; Zhang B; Pan M; Cui J; Dai Y; Huang W; Qian H J Med Chem; 2017 Apr; 60(7):2930-2943. PubMed ID: 28301155 [TBL] [Abstract][Full Text] [Related]
12. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway. Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650 [TBL] [Abstract][Full Text] [Related]
13. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176 [TBL] [Abstract][Full Text] [Related]
14. Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway. Wang H; Jia XH; Chen JR; Wang JY; Li YJ Oncol Rep; 2016 Jun; 35(6):3659-68. PubMed ID: 27109742 [TBL] [Abstract][Full Text] [Related]
15. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Huang M; Jin J; Sun H; Liu GT Cancer Chemother Pharmacol; 2008 Nov; 62(6):1015-26. PubMed ID: 18270702 [TBL] [Abstract][Full Text] [Related]
16. Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1. Ma H; Cheng L; Hao K; Li Y; Song X; Zhou H; Jia L PLoS One; 2014; 9(1):e85113. PubMed ID: 24454800 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment. Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712 [TBL] [Abstract][Full Text] [Related]
18. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-ÎşB pathway. Jiang L; Wang P; Sun YJ; Wu YJ J Exp Clin Cancer Res; 2019 Jun; 38(1):265. PubMed ID: 31215501 [TBL] [Abstract][Full Text] [Related]
19. Overcoming of P-glycoprotein-mediated multidrug resistance in K562/A02 cells using riccardin F and pakyonol, bisbibenzyl derivatives from liverworts. Ji M; Shi Y; Lou H Biosci Trends; 2011; 5(5):192-7. PubMed ID: 22101374 [TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]